Low-level laser therapy (LLLT) attenuates RhoA mRNA expression in the rat bronchi smooth muscle exposed to tumor necrosis factor-alpha
- PMID: 20393772
- DOI: 10.1007/s10103-010-0766-0
Abstract
Low-level laser therapy (LLLT) has been found to produce anti-inflammatory effects in a variety of disorders. Bronchial smooth muscle (BSM) hyperreactivity is associated with increased Ca+2 sensitivity and increased RhoA mRNA expression. In the current study, we investigated if LLLT could reduce BSM contraction force and RhoA mRNA expression in tumor necrosis factor-alpha (TNF-alpha)-induced BSM hyperreactivity. In the study, 112 male Wistar rats were divided randomly into 16 groups, and BSM was harvested and suspended in TNF-alpha baths for 6 and 24 h, respectively. Irradiation with LLLT was performed with a wavelength of 660 nm for 42 s with a dose of 1.3 J/cm2. This LLLT dose was administered once in the 6-h group and twice in the 24-h group. LLLT significantly decreased contraction force in BSM at 6 h (TNF-alpha + LLLT: 11.65+/-1.10 g/100 mg of tissue) (F=3115) and at 24 h (TNF-alpha+ LLLT: 14.15+/-1.1 g/100 mg of tissue) (F=3245, p<0.05) after TNF-alpha, respectively, when compared to vehicle-bathed groups (control). LLLT also significantly decreased the expression of RhoA mRNA in BSM segments at 6 h (1.22+/-0.20) (F=2820, p<0.05) and 24 h (2.13+/-0.20) (F=3324, p<0.05) when compared to BSM segments incubated with TNF-alpha without LLLT irradiation. We conclude that LLLT administered with this protocol, reduces RhoA mRNA expression and BSM contraction force in TNF-alpha-induced BSM hyperreactivity.
Similar articles
- Low level laser therapy (LLLT): attenuation of cholinergic hyperreactivity, beta(2)-adrenergic hyporesponsiveness and TNF-alpha mRNA expression in rat bronchi segments in E. coli lipopolysaccharide-induced airway inflammation by a NF-kappaB dependent mechanism.Lasers Surg Med. 2009 Jan;41(1):68-74. doi: 10.1002/lsm.20735.PMID: 19143014
- Effect of low level laser therapy on bronchial hyper-responsiveness.Lasers Med Sci. 2009 Jul;24(4):567-76. doi: 10.1007/s10103-008-0612-9. Epub 2008 Nov 12.PMID: 19005736
- TNF-alpha augments the expression of RhoA in the rat bronchus.J Smooth Muscle Res. 2004 Feb;40(1):25-34. doi: 10.1540/jsmr.40.25.PMID: 15170075
- MicroRNAs and their therapeutic potential for human diseases: MiR-133a and bronchial smooth muscle hyperresponsiveness in asthma.J Pharmacol Sci. 2010;114(3):264-8. doi: 10.1254/jphs.10r10fm. Epub 2010 Oct 9.PMID: 20953121Review.
- Rho-kinase as a drug target for the treatment of airway hyperrespon-siveness in asthma.Mini Rev Med Chem. 2006 Mar;6(3):339-48. doi: 10.2174/138955706776073402.PMID: 16515473Review.
Cited by 4articles
- Does low level laser therapy has effects on inflammatory biomarkers IL-1β, IL-6, TNF-α, and MMP-13 in osteoarthritis of rat models-a systemic review and meta-analysis.Lasers Med Sci. 2021 Apr;36(3):475-484. doi: 10.1007/s10103-020-03124-w. Epub 2020 Aug 24.PMID: 32833088
- Photobiomodulation guided healing in a sub-critical bone defect in calvarias of rats.Laser Ther. 2019 Sep 30;28(3):171-179. doi: 10.5978/islsm.28_19-OR-13.PMID: 32009730Free PMC article.
- LASER versus electromagnetic field in treatment of hemarthrosis in children with hemophilia.Lasers Med Sci. 2015 Nov;30(8):2179-87. doi: 10.1007/s10103-015-1794-6. Epub 2015 Aug 26.PMID: 26306883Clinical Trial.
- Effect of low-level laser therapy on the expression of inflammatory mediators and on neutrophils and macrophages in acute joint inflammation.Arthritis Res Ther. 2013;15(5):R116. doi: 10.1186/ar4296.PMID: 24028507Free PMC article.
References
- Curr Opin Cell Biol. 1991 Feb;3(1):98-104 - PubMed
- Nature. 1990 Jul 19;346(6281):274-6 - PubMed
- Pflugers Arch. 1990 Sep;417(1):21-8 - PubMed
- J Physiol. 1999 Jul 15;518 ( Pt 2):561-9 - PubMed
- J Smooth Muscle Res. 2003 Dec;39(6):221-8 - PubMed
- Mol Pharmacol. 2000 May;57(5):976-83 - PubMed
- J Clin Invest. 1993 Jun;91(6):2673-84 - PubMed
- Drugs. 2005;65(10):1355-65 - PubMed
- Am J Respir Cell Mol Biol. 1999 Jun;20(6):1190-200 - PubMed
- Res Commun Mol Pathol Pharmacol. 1999;106(1-2):77-85 - PubMed
- J Pharmacol Sci. 2004 Aug;95(4):479-82 - PubMed
- Br J Pharmacol. 1995 Jan;114(1):4-5 - PubMed
- Lasers Med Sci. 2005;20(1):11-20 - PubMed
- Lasers Med Sci. 2009 Jul;24(4):567-76 - PubMed
- Vopr Kurortol Fizioter Lech Fiz Kult. 2006 Mar-Apr;(2):8-10 - PubMed
- Thorax. 2002 Jun;57(6):524-7 - PubMed
- J Biochem. 2005 Jun;137(6):751-6 - PubMed
- Science. 1996 Jul 12;273(5272):245-8 - PubMed
- Lasers Surg Med. 2009 Jan;41(1):68-74 - PubMed
- Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1995 Jul;111(3):351-7 - PubMed
- Br J Pharmacol. 1999 Jun;127(3):597-600 - PubMed
- Lasers Surg Med. 2006 Sep;38(8):773-8 - PubMed
- Clin Exp Allergy. 1995 Nov;25(11):1038-44 - PubMed
- Br J Pharmacol. 2001 Jul;133(6):886-90 - PubMed
- Science. 1998 Jun 26;280(5372):2109-11 - PubMed
- J Smooth Muscle Res. 2004 Oct;40(4-5):155-67 - PubMed
- Nature. 1997 Oct 30;389(6654):990-4 - PubMed
- Pulm Pharmacol Ther. 2000;13(1):25-9 - PubMed
- J Physiol. 1996 Oct 15;496 ( Pt 2):317-29 - PubMed
- Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L214-9 - PubMed
- Respir Res. 2006 Sep 26;7:121 - PubMed
- J Smooth Muscle Res. 2004 Feb;40(1):25-34 - PubMed
- Am J Physiol. 1995 May;268(5 Pt 1):L739-46 - PubMed
- Eur J Pharmacol. 2000 Feb 11;389(1):103-6 - PubMed
- Physiol Rev. 2003 Oct;83(4):1325-58 - PubMed
- Am J Physiol. 1998 Oct;275(4 Pt 1):L748-55 - PubMed
- Science. 1998 Jun 26;280(5372):2112-4 - PubMed
- EMBO J. 1996 May 1;15(9):2208-16 - PubMed
- J Allergy Clin Immunol. 1991 Oct;88(4):561-71 - PubMed
- Am J Physiol. 1997 Oct;273(4 Pt 1):L775-81 - PubMed
- Am J Physiol. 1994 Oct;267(4 Pt 1):L398-405 - PubMed
- Am J Respir Cell Mol Biol. 1992 Oct;7(4):385-92 - PubMed
- J Biol Chem. 2002 Jun 28;277(26):23441-6 - PubMed
- J Biol Chem. 1999 Dec 24;274(52):37385-90 - PubMed